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AT1 Receptor A/C1166 Polymorphism Contributes
to Cardiac Hypertrophy in Subjects With
Hypertrophic Cardiomyopathy
Arthur P.R.M. Osterop, Marcel J.M. Kofflard, Lodewijk A. Sandkuijl, Folkert J. ten Cate, Rob Krams,
Maarten A.D.H. Schalekamp, A.H. Jan Danser
Abstract—The development of left ventricular hypertrophy (LVH) in subjects with hypertrophic cardiomyopathy (HCM)
is variable, suggesting a role for modifying factors such as angiotensin II. We investigated whether the angiotensin II
type 1 receptor (AT1-R) A/C1166 polymorphism, the angiotensin-converting enzyme (ACE) insertion/deletion (I/D)
polymorphism, and/or plasma renin influence LVH in HCM. Left ventricular mass index (LVMI) and interventricular
septal thickness were determined by 2-dimensional echocardiography in 104 genetically independent subjects with
HCM. Extent of hypertrophy was quantified by a point score (Wigle score). Plasma prorenin, renin, and ACE were
measured by immunoradiometric or fluorometric assays, and ACE and AT1-R genotyping were performed by
polymerase chain reactions. The ACE D allele did not affect any of the measured parameters except plasma ACE
(P,0.04). LVMI was higher (P,0.05) in patients carrying the AT1-R C allele (19068.3 g/m2) than in AA homozygotes
(16867.2 g/m2), and similar patterns were observed for interventricular septal thickness (23.060.7 versus
21.660.7 mm) and Wigle score (7.060.3 versus 6.360.3). Plasma renin was higher (P50.05) in carriers of the C allele
than in AA homozygotes. Multivariate regression analysis, however, revealed no independent role for renin in the
prediction of LVMI. Plasma prorenin and ACE were not affected by the AT1-R A/C1166 polymorphism, nor did the ACE
and AT1-R polymorphisms interact with regard to any of the measured parameters. We conclude that the AT1-R C1166
allele modulates the phenotypic expression of hypertrophy in HCM, independently of plasma renin and the ACE
I/D polymorphism. (Hypertension. 1998;32:825-830.)
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Hypertrophic cardiomyopathy (HCM) is characterized byidiopathic myocardial hypertrophy. HCM occurs as a
familial disorder, with an autosomal dominant pattern of
inheritance, as well as in sporadic clinical presentation.
Currently, 6 genes (b-myosin heavy chain, cardiac troponin
T, a-tropomyosin, cardiac myosin binding protein-C, cardiac
essential light chain-1, and cardiac regulatory light chain)
have been identified that may cause HCM.1–5 Patients with
identical gene mutations display variable clinical manifesta-
tions or even fail to express the disease.6–8 Other factors,
genetic as well as environmental, may therefore modify the
phenotypic expression of the mutated gene.
It is now generally believed that angiotensin (Ang) II,
formed by angiotensin-converting enzyme (ACE) from Ang
I, is not only a potent vasoconstrictor but also an important
modulator of cardiac hypertrophy.9,10 ACE inhibition induces
regression of cardiac hypertrophy, independent of load, and
prevents dilatation and remodeling of the ventricle after
myocardial infarction (MI).11–14 Cardiac ACE levels are in-
creased after MI,11,15,16 as well as during pressure overload–
induced left ventricular hypertrophy (LVH).17 The ACE
levels in the human heart are in part determined by the
so-called insertion/deletion (I/D) polymorphism, with sub-
jects with the DD genotype having higher tissue ACE levels
than subjects with II or ID genotypes.18 According to
some19–21 but not all22,23 studies, the frequency of the D allele
is higher in patients with HCM. Moreover, the extent of
hypertrophy in subjects with HCM is influenced by the ACE
I/D polymorphism,20,22,23 suggesting that Ang II may modify
the phenotypic expression of hypertrophy in HCM. The latter
association may depend on the underlying gene mutation,
since it was found only in subjects with mutations in the Arg
403 codon of the b-myosin heavy chain gene.23
Ang II exerts most of its known cellular actions through the
angiotensin II type 1 receptor (AT1-R).24 Recently, the C
allele of a polymorphism located in the 39 untranslated region
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of the AT1-R gene (corresponding to an adenine/cytosine
[A/C] substitution at the 1166 position) has been shown to
increase synergistically the risk of MI in subjects carrying the
ACE D allele.25
It was the aim of the present study to investigate whether the
AT1-R C allele influences the extent of hypertrophy in HCM, eg,
through an interaction with the ACE D allele. Because cardiac
angiotensin generation depends largely on kidney-derived
(pro)renin taken up from the circulation,26–28 we also studied the
relationship between plasma (pro)renin, cardiac hypertrophy,
and the AT1-R C allele in subjects with HCM.
Methods
Patients
One hundred sixteen patients with HCM (aged 21 to 81 years;
median, 47 years) visiting the Hypertrophic Cardiomyopathy Clinic
at the Thorax Center of the Academic Hospital “Dijkzigt” between
December 1994 and January 1997 for routine follow-up were
included in the study. HCM had been diagnosed on the basis of
echocardiographic criteria showing a nondilated, hypertrophied left
ventricle (any wall thickness .15 mm) in the absence of known
causes of LVH such as systemic hypertension or valvular disease.29
From each patient, a peripheral venous blood sample was collected
for measurement of plasma prorenin, renin, and ACE and for the
extraction of genomic DNA. Patients using ACE inhibitors (n57)
were excluded from the study because of interference with the
measurement of plasma ACE. Of the remaining 109 subjects, 41 had
a sporadic form of HCM and 50 had at least 1 other affected
first-degree family member. The family history of HCM was
unknown in 18 patients. To avoid potential bias introduced by the
presence of genetically dependent samples (relatives), we randomly
selected 1 patient per family. This resulted in a final cohort of 104
genetically independent patients, of whom 30 were receiving a
b-adrenergic antagonist, 44 a calcium channel blocker, and
8 a diuretic.
The study was approved by the internal review board, and patients
gave informed consent.
Echocardiographic Methods
Two-dimensional echocardiography was performed with commercially
available equipment (Toshiba Sonolayer SSH-140A System). The heart
was visualized in a number of cross-sectional planes using standard
transducer positions, and images were recorded on videotape for off-line
analysis. Echocardiographic analysis was performed by 2 physicians
who were blinded to the results of the genotyping studies.
Interventricular septal thickness (IVS) was measured in diastole from the
parasternal short-axis view at the level of the papillary muscles. The
magnitude of LVH was determined by calculating left ventricular mass
(LVM, g) according to the method described by Devereux et al30:
LVM50.8(1.04[(IVS1LVED1LVPW)32LVED3])10.6 g, where LVED
is the left ventricular end-diastolic diameter and LVPW is the end-diastolic
thickness of the posterior wall. LVM was indexed (LVMI, g/m2) to body
surface area (BSA).
Systolic anterior motion (SAM) of the anterior leaflet of the mitral
valve was assessed from the 2-dimensional images and graded as 0
(absent), 11 (mild [minimal mitral-septal distance .10 mm during
systole]), 21 (moderate [minimal mitral-septal distance #10 mm
during systole]), or 31 (marked [brief or prolonged contact between
the mitral valve and septum]).31
Peak LV outflow tract gradient at rest was estimated using the
modified Bernoulli equation, P54V2, where P is the pressure gradient
and V is the velocity determined by Doppler echocardiography.
Because the echocardiographic measurement of LVMI may not
truly reflect the extent of hypertrophy and the involvement (or lack
thereof) of the distal (apical) half of the septum or lateral wall, the
extent of hypertrophy was also assessed by a semiquantitative point
score method developed by Wigle et al.32 A maximum of 10 points
are given: 1 to 4 points for septal hypertrophy based on magnitude of
thickness, 2 points for extension of hypertrophy beyond the level of
the papillary muscles (basal two thirds of septum), 2 points for
extension of hypertrophy to the apex (total septal involvement), and
2 points for extension of hypertrophy into the lateral wall.
Biochemical Measurements
Blood (5 mL) was collected into tubes containing trisodium citrate
(final concentration in blood, 0.026 mol/L). The blood was centri-
fuged at 3000g for 10 minutes at room temperature, and plasma was
stored in 1-mL aliquots at 270°C. Shortly before assay, the samples
were rapidly thawed and kept at room temperature. All assays were
performed in duplicate.
Immunoreactive renin was quantified in 200 mL plasma with an
immunoradiometric assay kit (Nichols Institute), following the
methods proposed by Derkx et al.33 Prorenin was activated nonpro-
teolytically by incubation with the renin inhibitor remikiren, and its
concentration was calculated by subtracting the level of renin from
that of total renin (ie, the level obtained after activation). The renin
and prorenin levels are expressed as milliunits per liter, using the
international human kidney renin standard MRC 68/356 (Medical
Research Council, National Institute of Biological Standards and
Control, London, UK) as a reference. The normal range in plasma is
8 to 55 mU/L for renin and 88 to 390 mU/L for prorenin.33
ACE activity was measured with a commercial kit (ACE Color,
Fujirebio); its normal range in plasma is 7 to 20 U/L.34
Genetic Analysis
Peripheral leukocytes, obtained after centrifugation of 5 mL blood
(see Biochemical Measurements), were used to isolate genomic
DNA in H2O using the QIAamp Bloodkit (Qiagen Inc). DNA
concentrations varied from 25 to 50 ng/mL.
The determination of the ACE gene I/D polymorphism was based
on the triple-primer polymerase chain reaction (PCR) method de-
scribed by Evans et al.35 This method, which avoids mistyping of ID
as DD,36 was modified into 2 separate PCRs. The first PCR
encompassed the entire I/D region. Using the sense oligonucleotide
primer 59-GCTGGAGACCACTCCCATCCTTTCT-39 and the anti-
sense primer 59-TAGACCTCCACGAGTCCCCTGCAT-39, 2 frag-
ments of 493 bp and 781 bp were amplified corresponding to the D
and I alleles, respectively. In the other PCR, an insertion-specific
sense primer, 59-TGGGATTABPCAGGCGTGATACAG-39, was
used with the above-mentioned antisense primer. This PCR ampli-
fied a 460-bp fragment corresponding to the I allele. PCR reactions
were performed on 2 mL genomic DNA in a final volume of 25 mL
containing 0.4 nmol/L of each primer, 1.5 mmol/L MgCl2,
75 mmol/L Tris-HCl (pH 9.0), 20 mmol/L (NH4)2SO4, 0.01%
(wt/vol) Tween 20, 0.2 mmol/L of each dNTP, and 0.5 U Goldstar
DNA polymerase (Eurogentec Inc). The amplification profile in-
cluded an initial denaturation at 96°C for 3 minutes and 35 cycles of
denaturation at 96°C for 30 seconds, annealing at 60°C for 15
seconds, and extension at 72°C for 60 seconds with a final extension
time of 10 minutes. The PCR products were separated by electro-
phoresis on 3% agarose gels and visualized by ethidium bromide
staining.
The AT1-R gene A/C1166 polymorphism was determined using
PCR, spanning the polymorphic site, and subsequent fluorescent
sequence analysis of the PCR product. The sense primer in the PCR
was extended at the 59 site, with a nucleotide stretch homologous to
the sequence analysis primer (228M13Rev) shown in italics, 59-
AGGAAACAGCTATGACCATGACATGTTCGAAACCTGTCCAT-
AAAG-39, and the antisense primer was 59-CGGTTCAGTCC-
ACATAATGC-39. These primers allowed the amplification of a
genomic DNA segment of 139 bp that contained the polymorphic
site 88 bp downstream from the sequencing primer. Reactions were
performed on 1 mL genomic DNA in a final volume of 15 mL
containing 0.2 nmol/L sense primer, 0.4 nmol/L antisense primer,
1.5 mmol/L MgCl2, 75 mmol/L Tris-HCl (pH 9.0), 20 mmol/L
(NH4)2SO4, 0.01% (wt/vol) Tween 20, 0.2 mmol/L of each dNTP,
and 0.5 U Goldstar DNA polymerase (Eurogentec Inc). The ampli-
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fication profile included an initial denaturation at 96°C for 3 minutes
and 35 cycles of denaturation at 96°C for 30 seconds, annealing at
50°C for 15 seconds, and extension at 72°C for 60 seconds with a
final extension time of 10 minutes. After completion of the PCR, 6
mL was used to perform sequence analysis reactions using the
fluorophore-labeled “228M13Rev DYEnamic ET-primer” and the
“DYEnamic direct cycle sequencing kit with 7-deaza dGTP” accord-
ing to the instructions of Amersham International. The sequence
reaction products were separated by electrophoresis in polyacryl-
amide gels and analyzed in an ABI Prism 377 automatic DNA
sequencer (Perkin-Elmer Corp) using the accompanying software.
Statistical Analysis
Data are expressed as counts, mean6SEM, or as median and range.
Statistical analysis was performed with the SPSS 7.0 statistical
package. The Hardy-Weinberg equilibrium was tested by a x2 test.
To analyze differences between carriers of the C or D allele and the
noncarriers, we collapsed the AC and CC genotypes and the ID and
DD genotypes into 2 groups (AC1CC and ID1DD, respectively).
Because of a nonnormal distribution of most parameters, differences
between carrier and noncarrier groups were tested by the Mann-
Whitney U test. Univariate and multivariate regression analyses were
conducted to determine the percentage of explained variance in
LVMI that is accounted for by the genotypes of the candidate
modifier genes and other variables. Both polymorphisms were tested
as codominant 0, 1, or 2 ordinal variables (presence of 0, 1, or 2 C
or D alleles). In the multivariate regression analysis, the 2 poly-
morphisms, gender (male50, female51), age, peak LV outflow tract
gradient, and plasma renin concentration were considered indepen-
dent variables. Plasma prorenin, plasma ACE, and SAM were
excluded from this analysis because of their physiological interrela-
tionship with plasma renin, ACE genotype, and peak LV outflow
tract gradient, respectively. These interrelationships were consoli-
dated by respective high correlations: plasma renin (r50.680,
P,0.001), ACE genotype (r50.389, P50.003), and peak LV
outflow tract gradient (r50.766, P,0.001).
Results
The distributions of the ACE I/D and the AT1-R A/C1166
genotypes in 104 genetically independent HCM patients are
shown in Table 1. The frequencies of the ACE I and D alleles
(0.50 and 0.50, respectively) and the AT1-R A and C alleles
(0.74 and 0.26, respectively) were similar to previously reported
numbers in normal white populations.18,25,37,38 Genotype frequen-
cies were in agreement with Hardy-Weinberg equilibrium.
Table 2 lists the characteristics of the HCM patients
according to ACE I/D genotype. No differences with regard
to gender, age, BSA, or any of the cardiac parameters were
found between carriers of the D allele and subjects with the II
genotype. Plasma renin and prorenin levels (Table 2), as well
as the percentage of patients taking b-adrenergic antagonists,
calcium channel blockers, or diuretics (data not shown), were
also similar in II and ID1DD patients. In accordance with
previous studies,39,40 plasma ACE activity was highest in DD
subjects and intermediate in ID subjects. Regression analysis
showed that the ACE genotype accounted for 15.1% of the
variability in plasma ACE activity (r50.389, P50.003).
Table 3 lists the characteristics of the HCM patients
according to AT1-R A/C1166 genotype. The percentage of
patients taking b-adrenergic antagonists, calcium channel
blockers, or diuretics did not differ between AA and AC1CC
patients (data not shown). Gender, age, BSA, and peak LV
outflow tract gradient were not associated with the AT1-R
A/C1166 polymorphism. However, LVM, LVMI, and plasma
renin were significantly higher in subjects carrying 1 or 2 C
alleles than in AA homozygotes, and similar patterns were
observed for IVS and Wigle score. Regression analysis





Sum (%)AA AC CC
II 15 6 3 24 (23%)
ID 33 21 3 57 (55%)
DD 9 12 2 23 (22%)
Sum (%) 57 (55%) 39 (38%) 8 (8%) 104 (100%)
TABLE 2. Characteristics of HCM Patients According to ACE I/D Genotype
Parameter
ACE Genotype P
II (n524) ID (n557) DD (n523) ID1DD vs II
Gender, M/F 14/10 36/21 15/8 0.632
Age, y 49.863.3 46.262.0 48.062.8 0.358
BSA, m2 1.8060.05 1.8560.02 1.8860.04 0.159
IVS, mm 22.060.9 22.360.7 22.361.1 0.956
LVM, g 326.5622.2 331.1614.1 315.2618.4 0.923
LVMI, g/m2 182.5611.9 180.368.1 167.068.3 0.725
Wigle score, 1–10 6.860.4 6.660.3 6.560.6 0.743
SAM, 0/11/21/31* 4/1/7/9 11/9/11/22 5/4/8/4 0.369
Gradient, mm Hg 55.869.4 47.665.4 36.167.9 0.395
Prorenin, mU/L 156 (86–1339) 173 (47–813) 141 (28–299) 0.540
Renin, mU/L 20.7 (7.8–202) 21.0 (3.0–85) 20.3 (3.0–54) 0.383
ACE, U/L 8.760.5 9.960.4 11.260.5 0.038
Values are counts, mean6SEM, or median (range). Mann-Whitney U test was used to test for
differences between the ID1DD and II subjects. Gradient indicates peak LV outflow tract gradient;
Wigle score, semiquantitative point score assessing the extent of hypertrophy.
*SAM could not be determined in 9 patients.
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showed that the AT1-R genotype accounted for 4.3% of the
variability of LVM (r50.208, P50.034), 4.5% of the vari-
ability of LVMI (r50.213, P50.031), and 4.2% of the
variability of plasma renin (r50.204, P50.037). SAM was
lower in carriers of the C allele, but regression analysis
revealed no relationship between AT1-R genotype and SAM
(r50.152, P50.138).
Using a 2-factor ANOVA, no interaction was observed
between the ACE D allele and the AT1-R C allele with regard
to any of the measured parameters.
Plasma renin, plasma prorenin, and the sum of plasma
renin and plasma prorenin (plasma total renin) did not
correlate with LVM, LVMI, or any of the other cardiac
parameters (data not shown).
Multivariate regression analysis showed that age, peak LV
outflow gradient, and the AT1-R A/C1166 polymorphism, but
not gender, plasma renin, or the ACE I/D polymorphism,
were significant predictors of LVMI (Table 4).
Discussion
The present study shows that the AT1-R genotype influences the
magnitude of LVH in subjects with HCM. LVM and LVMI
were significantly higher in patients carrying the C allele than in
AA homozygotes, and a similar pattern was observed for IVS
and Wigle score, the latter being a semiquantitative score
reflecting the extent of cardiac hypertrophy.32 No relationship
with SAM and peak LV outflow tract gradient was observed.
Interestingly, plasma renin but not plasma prorenin was higher in
subjects carrying the C allele than in AA homozygotes.
The AT1-R A/C1166 polymorphism is located at the 59 site of
the 39 untranslated region of the gene. This polymorphism is
probably not functional but might be in linkage equilibrium with
an unidentified functional variant affecting the structure or
function of the AT1-R (or adjacent unknown genes). Tiret et al25
have speculated that the downregulation of the AT1-R gene in
response to Ang II is altered in subjects with the C allele. Such
altered downregulation, which is most likely tissue-specific,41–44
would not only offer an explanation for our findings on cardiac
hypertrophy but it might also explain the increased renin levels
in patients carrying the C allele, since Ang II stimulates cardiac
hypertrophy9,45 and regulates renin release46,47 via AT1-R. In line
with our findings, Hein et al48 recently showed that overexpres-
sion of the AT1-R in the mouse leads to an increase in cardiac
mass and myocyte hypertrophy.
The C allele has been associated with hypertension,38,49 aortic
stiffness,50 the development of coronary artery stenosis,51 and
coronary artery vasoconstriction.52 The frequency of the C allele
in the HCM subjects of the present study was similar to that
reported previously in the general population.25,50 Thus, the
AT1-R A/C1166 polymorphism is not associated with HCM as
such but rather modulates the phenotypic expression of hyper-
trophy in subjects with HCM. Such modulation might explain
why individuals with the same HCM mutation show a signifi-
cant variability in the magnitude of LVH.6–8
The ACE I/D polymorphism has also been reported to
account for some of the variability of LVMI in HCM
subjects.20,22 This could not be confirmed in the present study,
although our data do support the previously described asso-
ciation between plasma ACE and ACE genotype.39,40 It is
possible that the influence of the ACE genotype in HCM
TABLE 3. Characteristics of HCM Patients According to AT1-R A/C1166 Genotype
Parameter
AT1-R Genotype P
AA (n557) AC (n539) CC (n58) AC1CC vs AA
Gender, M/F 33/24 29/10 3/5 0.288
Age, y 48.662.1 45.762.1 47.466.9 0.332
BSA, m2 1.8460.03 1.8860.03 1.7560.06 0.796
IVS, mm 21.660.7 22.960.7 23.462.3 0.111
LVM, g 306.2612.5 350.1616.2 356.5649.3 0.010
LVMI, g/m2 167.967.2 186.568.1 205.4630.3 0.010
Wigle score, 1–10 6.360.3 6.960.3 7.360.8 0.109
SAM, 0/11/21/31* 7/8/14/23 12/5/8/10 1/1/4/2 0.045
Gradient, mm Hg 53.165.5 37.866.4 43.6616.6 0.078
Prorenin, mU/L 161 (28–741) 147 (48–1339) 228 (86–813) 0.627
Renin, mU/L 17.0 (3.0–55) 22.7 (3.0–202) 24.6 (10.2–85) 0.054
ACE, U/L 10.260.4 9.660.4 9.960.8 0.225
Values are counts, mean6SEM, or median (range). Mann-Whitney U test was used to test for
differences between the AC1CC and AA subjects. Gradient indicates peak LV outflow tract gradient;
Wigle score, semiquantitative point score assessing the extent of hypertrophy.
*SAM could not be determined in 9 patients.
TABLE 4. Multivariate Regression Analysis of Factors With
Potential Effect on LVMI
Parameter b SEM P
Gender (male50, female51) 7.045 11.015 0.524
Age, y 20.898 0.356 0.013
ACE genotype, No. of D alleles 28.103 8.039 0.316
AT1-R genotype, No. of C alleles 20.645 8.569 0.018
Renin, mU/L 20.159 0.247 0.521
Gradient, mm Hg 0.276 0.134 0.043
Gradient indicates peak LV outflow tract gradient.
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subjects depends on the specific disease gene mutation.23 We
did not determine the underlying gene mutations in our HCM
patients. The presence of different sarcomeric gene mutations
in our population, however, might offer an explanation for the
lack of association between ACE genotype and LVH in the
present cohort. It might also explain why Brugada et al53 did
not find an association between the AT1-R C allele and
cardiac hypertrophy in their patients. In addition, the HCM
patients selected by Brugada et al had a less severe form of
HCM (wall thickness $13 mm) than those selected in the
present study (wall thickness .15 mm). This may have
enhanced our chance of finding a significant association
between hypertrophy and the AT1-R C allele.23
Theoretically, the high tissue ACE levels found in DD
subjects18 might lead to high tissue Ang II levels and thereby
enhance the AT1-R C allele-related effects on hypertrophy.
Such synergy has been described for the risk of MI.25 Any
interaction between the AT1-R C allele and the ACE D allele,
however, will be obscured by the elevated plasma renin levels
found in HCM patients carrying the C allele. High plasma
renin levels, via uptake of renin by the heart,26,27,54 will also
lead to high cardiac Ang II levels. Thus, cardiac Ang II levels
may already be high in AC and CC subjects independently of
the ACE gene polymorphism, and this could explain the lack
of interaction between the 2 gene polymorphisms of the
renin-angiotensin system in the present study.
Recently, plasma renin activity was found to correlate
positively with LVM in healthy young adults.10 One may
therefore argue that the elevated plasma renin levels in
subjects carrying the C allele are the underlying reason for the
relationship between the C allele and cardiac hypertrophy.
However, plasma renin did not correlate with either LVM or
LVMI in the present study, and multivariate regression
analysis revealed no independent effect of plasma renin after
correction for AT1-R genotype. Thus, it appears that in HCM
subjects, other factors related to the AT1-R A/C1166 poly-
morphism (eg, cardiac AT1-R density) are more important
determinants of cardiac hypertrophy than plasma renin.
In addition to the AT1-R A/C1166 polymorphism, age and peak
LV outflow gradient were also independent predictors of LVMI.
Both associations have been reported before.55–59 LVMI de-
creases with age, most likely because progressive wall thinning
occurs gradually over time in HCM patients.55,56 Mitral leaflet-
septal contact determines the magnitude of the pressure gradient
in the LV outflow tract, and more marked SAM of the mitral
valve is associated with an augmentation of LVH.55–59
In conclusion, the results of this study support a modulat-
ing role for the AT1-R A/C1166 polymorphism in the develop-
ment of LVH in patients with HCM, independent of age,
gender, peak LV outflow gradient, plasma renin, and the ACE
I/D polymorphism.
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